Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback